Joincare Pharmaceutical Group Industry Co., Ltd

Quick facts

Phase 3 pipeline

• JKN2301 Dry Suspension
  JKN2301 is an investigational dry suspension formulation designed to improve bioavailability and patient compliance for an undisclosed active pharmaceutical ingredient.
• JKN2401 Injection · Endocrinology / Diabetes
  JKN2401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.

Phase 2 pipeline

• JKN2304 Inhalation Solution
• JKN24011
• JKN2403 Tablets

Phase 1 pipeline

• DBM-1152A
• DBM-1152A Inhalation Solution
• JKN2306
• JKN2501

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Joincare Pharmaceutical Group Industry Co., Ltd portfolio CI brief
• Joincare Pharmaceutical Group Industry Co., Ltd pipeline updates RSS